Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Final Results of the Eradic Trial from the Filo Group

• Published in: Blood 2024-11, Vol.144 (Supplement 1), p.584-584
• Main Authors: Michallet, Anne Sophie, Letestu, Remi, Legarff, Magali, Morisset, Stéphane, Aurran-Schleinitz, Therese, Laribi, Kamel, Levy, Vincent, Simon, Laurence, Roos Weil, Damien, Dilhuydy, Marie Sarah, Tomowiak, Cecile, Dartigeas, Caroline, Guieze, Romain, Tournilhac, Olivier, Ferrant, Emmanuelle, De Guibert, Sophie, Feugier, Pierre, Merabet, Fatiha, Lepretre, Stéphane, Carassou, Philippe, Gay, Julie, Hivert, Benedicte, Fornecker, Luc-Matthieu, Dupuis, Jehan, Molina, Lysiane, Villemagne, Bruno, Cartron, Guillaume, Drenou, Bernard, Benbrahim, Omar, Cahu, Xavier, Nguyen Khac, Florence, Rouillé, Valerie, Ysebaert, Loic, Quinquenel, Anne
• Format: Article
• Language: English
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood-2024-194593

With the emergence of targeted therapies, defining the best strategy for first-line treatment in patients with chronic lymphocytic leukemia (CLL) has become challenging. The aim of the ERADIC phase 2 trial (NCT04010968) was to compare the efficacy of a standard fludarabine-cyclophosphamide-rituximab (FCR) regimen to that of a combination of ibrutinib and venetoclax (IV), guided by measureable residual disease (MRD), in fit patients with CLL of intermediate risk defined by either unmutated IGHV status, del(11q) or complex karyotype in the absence of TP53 alteration. MRD was assessed in bone marrow (BM) or peripheral blood (PB) by flow cytometry. After a lead-in phase of ibrutinib as a single agent from month (M)1 to M3, the total duration of treatment with the IV combination was based on M9 BM-MRD. If it was